Is CTSO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CTSO. It does not provide personalized investment advice.

CTSO (Cytosorbents Corp.) Stock Analysis - Financials

Cytosorbents Corp. (CTSO) is a publicly traded Healthcare sector company. As of October 23, 2026, CTSO trades at $5.41 with a market cap of $16.86M and a P/E ratio of -31.58. CTSO moved -10.48% today. Year to date, CTSO is -54.87%; over the trailing twelve months it is -64.65%. Its 52-week range spans $2.84 to $27.80. Analyst consensus is neutral with an average price target of $15.00. Rallies surfaces CTSO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are CTSO's key financials?

CTSO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CTSO recently traded at $5.41. Market cap is $16.86M. P/E ratio is -31.58. Revenue is $37.06M.

CTSO Key Metrics

Key financial metrics for CTSO
Metric	Value
Price	$5.41
Market Cap	$16.86M
P/E Ratio	-31.58
EPS	$-0.13
Dividend Yield	0.00%
52-Week High	$27.80
52-Week Low	$2.84
Volume	23.31K
Avg Volume	0
Revenue (TTM)	$37.06M
Net Income	$-8.20M
Gross Margin	71.48%

CTSO Analyst Consensus

1 analysts cover CTSO: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $15.00.

Common questions about CTSO

What are CTSO's key financials?: CTSO financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CTSO recently traded at $5.41. Market cap is $16.86M. P/E ratio is -31.58. Revenue is $37.06M.
Is CTSO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CTSO. It does not provide personalized investment advice.